About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Worst And/Or Craziest Misconceptions | Main | Luc Montagnier Is Not Losing It. Luc Montagnier Has Lost It. »

May 29, 2012

GSK and Immune Response: Not Quite An Amicable Divorce

Email This Entry

Posted by Derek

Update: Immune Response Biopharma CEO David Buswell has left a detailed comment to this point, pointing out that it was his company that ended talks with GSK, and not the other way around. See here for the details.

GlaxoSmithKline has decided not to pursue further development of a potential vaccine therapy for multiple sclerosis, dumping former partner Immune Response BioPharma. We get that sort of headline all the time in this business - deals come, and deals go. What we don't get are press releases like these. The full unaltered text:

"Immune Response BioPharma, Inc. has the first MS Vaccine a first in class and best in class multiple sclerosis drug which restores deficient FOXP3+ T-Regs. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell

"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell

Y'know, in his way, this CEO is a breath of fresh air. Everyone thinks these things in such situations, but not many people put them out on the PR wires. This release seems to have transcribed directly from Mr. Buswell's (no doubt heated) statements at the time, which I'm sure accounts for the take-a-breath grammar. I'll follow NeuroVax's progress with interest to see who has the last laugh this time. . .

Comments (47) + TrackBacks (0) | Category: Business and Markets | The Central Nervous System


1. PPedroso on May 29, 2012 6:50 AM writes...

"GSK is a loser in the MS market and will continue to be a loser"

The trolling is strong in this one... This just made my day! :D

Permalink to Comment

2. MTK on May 29, 2012 7:10 AM writes...

That's a press release, not just some off the cuff remark noted by a reporter?


If I were on the Board of Immune Response I'd can Mr. Buswell pronto. You can't have your CEO releasing public statements like that.

a) It hurts your chances of signing another deal if he's around.


b) If that type of undisciplined behavior is acceptable in the CEO what does that say to any employee in dealing with people internal and external to the company?

I will you grant you it's funny, but good God, if I was working for Immune Response I'd be embarrassed, even if I thought every word he said were true. And if I were an investor, I'd be very worried about my investment.

Permalink to Comment

3. anon the II on May 29, 2012 7:12 AM writes...

I think it's kind o funny that Derek got a double post, just like lots of those in the comment section do.

Permalink to Comment

4. MTK on May 29, 2012 7:23 AM writes...

I guess Mr. Buswell can do and say whatever damn well he pleases. According to the Immune Response website he's the COO, CFO, acting CEO, and Board Chairman.

Permalink to Comment

5. ToughChoices on May 29, 2012 7:26 AM writes...

An intemperate outburst if ever there was one. Actually, Mr Boswell appears to overlook GSK's preeminent position in vaccines which provides one of its strongest revenue streams. Perhaps he'd also like to know that Moncef Slaoui was intimately involved in a real breakthrough in malaria vaccine development, ( To suggest Moncef and quite a few others don't know quite a bit about basic immunology is, frankly, risible! Good look to Immune Response BioPharma, MS is certainly an area of unmet medical need but such rebarbative comment from their CEO will do little to enhance their product's prospects. I'm sure those who made the call at GSK had good scientific reasons to justify it and Mr Boswell's response may just convince them that they made the right call.

Permalink to Comment

6. Anonymous on May 29, 2012 7:30 AM writes...

Good 'look' to ToughChoices when the next round of redundancies hits GSK House

Permalink to Comment

7. overthetop on May 29, 2012 7:37 AM writes...

Sounds like somebody is a sore loser. It's about time GSK dropped duds like this. Usually GSK has a knack for picking and sticking with real losers.

Permalink to Comment

8. Nick K on May 29, 2012 7:43 AM writes...

ToughChoices (Agilist and several other names) is just the GSK troll, ever ready with a sycophantic post. Incidentally, why does he always refer to the senior managers by their first names?

Permalink to Comment

9. myma on May 29, 2012 7:49 AM writes...

He left off "and a ninny ninny boo boo too".

Permalink to Comment

10. Cromulent1 on May 29, 2012 7:51 AM writes...

Rebarbative. I plan to use that three times in conversation today. Excellent.

Permalink to Comment

11. ToughChoices on May 29, 2012 7:54 AM writes...

Amazing! You state something even mildly favorable to GSK and you're accused of being a shil/troll/pr type, etc, ad nauseum! Do you expect all comments to be negative and objurgatory, #8? As for use of first names, that's pretty standard at GSK as it is at many companies and is testament to a generally open, science-driven, non-hierarchical company!

Permalink to Comment

12. Anonymous on May 29, 2012 7:56 AM writes...

We all know GSK has made some, ahem, 'interesting' choices for partners over the last few years but did they really work with this outfit? Really?

Stick this Buswell character into google along with the company name and you come across come interesting stuff!

Permalink to Comment

13. qetzal on May 29, 2012 8:06 AM writes...

What kind of PR person posts a direct transcription of their CEO's ungrammatic, spittle-flecked tirades as a press release? And also manages to misspell "zer0"?

What do you want to bet Buswell is acting PR Director, as well as acting CEO etc., and released this himself? He sounds like a royal pain to work with. I'd hate to have been the person at GSK who had to manage that partnership. (Much less an employee at IRBP!)

Permalink to Comment

14. partial agonist on May 29, 2012 8:15 AM writes...

If this is how this guy is to outsiders and for public display, it is not hard to imagine that he must be about 10-fold worse to his day-to-day co-workers. Note to Immune Response BioPharma employees: It isn't worth putting up with that (crap).

Permalink to Comment

15. PPedroso on May 29, 2012 8:19 AM writes...


Probably we will be something along this lines:

Permalink to Comment

16. anon on May 29, 2012 8:20 AM writes...

He talks about MS, you talk about vaccines. Maybe you're both right, but your rebuttal isn't relevant.

Permalink to Comment

17. ToughChoices on May 29, 2012 8:23 AM writes...

Derek's post opens with "GlaxoSmithKline has decided not to pursue further development of a potential vaccine therapy for multiple sclerosis...."
Seems invoking the GSK vaccine defese is highly germane in this context!

Permalink to Comment

18. Anon the III on May 29, 2012 8:24 AM writes...

Well, it certainly made me chuckle more than another press release that came out this morning, which we won't discuss on Derek's blog...

Permalink to Comment

19. Jumbo on May 29, 2012 8:39 AM writes...

Derek: You left out the most important sentence - "Immune Response BioPharma, Inc. Terminates Blockbuster MS Drug NeuroVax Partnership Discusions (sic) With GSK." GSK isn't giving up on a partnership. It is giving up on the NEGOTIATION of a partnership. IRBp is complaining about the deal negotiation process; they haven't even concluded the partnership! So what alternative partner do you think would even negotiate with this CEO?!? My word.

Permalink to Comment

20. anon2 on May 29, 2012 9:07 AM writes...

Sounds like a guy who has just lost his girlfriend to his arch enemy, and now does not have anyone left to take to the prom.

GSK may have learned something about negotiating price in potential deals over the last few years (that is the least they should have learned), and may no longer be as gullable as they have been in the past...well maybe some of the time they have learned. Also, this may be an indication for biotech valuations coming down to reality, better reflecting any one's opportunity for achieving approval and registration and making profit. The "self-importance" seen within many biotechs, particularly those with very limited portfolio missing reality, simply reflects their need to compete with Wall Street and the likes of Apple...maybe they now need to rewind, and consider Facebook.....

Permalink to Comment

21. Rick Wobbe on May 29, 2012 9:14 AM writes...

Anon the III, 18, If you're talking about the press release I think you're talking about, it's worth discussing because it is a good example of the kind of news that can be easily misinterpreted as bad news. Hopefully, investors in the company that cannot be named are smarter than that. Other blogs have picked it up.

Permalink to Comment

22. watcher on May 29, 2012 9:14 AM writes...

Involving "divorce" in this title makes it so much more dramatic in sugggesting that a marriage already had already taken place. Not the case there was not even a formal agreed-upon "engagement" by both partied, let along their parents!

Discussions around potential deals come & go all the's just that when one party can't manipulate the other adequately, most of the time they don't lash out so strongly in response, even though they probably do carry similar sentiment.

Permalink to Comment

23. watcher on May 29, 2012 9:14 AM writes...

Involving "divorce" in this title makes it so much more dramatic in sugggesting that a marriage already had already taken place. Not the case there was not even a formal agreed-upon "engagement" by both partied, let along their parents!

Discussions around potential deals come & go all the's just that when one party can't manipulate the other adequately, most of the time they don't lash out so strongly in response, even though they probably do carry similar sentiment.

Permalink to Comment

24. anchor on May 29, 2012 9:30 AM writes...

re•bar•ba•tive (r-bär b-t v) adj. Tending to irritate; repellent and I learned new vocabulary today!

Permalink to Comment

25. Hap on May 29, 2012 10:00 AM writes...

Someone needs to take away Mr. Buswell's crayons and Fisher-Price laptop and cell phone. I would also consider a new babysitter/homework helper who actually has a working command of (polite) English grammar.

If my CEO popped off like this, I wouldn't know whether to laugh or cry - since I couldn't update my resume while doing either, it probably wouldn't matter.

Permalink to Comment

26. David Formerly Known as a Chemist on May 29, 2012 10:47 AM writes...

From the company website:

"Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, President & acting CEO and is Chairman of the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Management & Leadership from Liberty University."

It even provides links to the graduating class list from each university to, uh, prove that he actually graduated from each (no Yahoo! debacle here!).

Permalink to Comment

27. Anon the III on May 29, 2012 11:10 AM writes...

Rick, 18, I completely agree, and thankfully the market seems to be coming round to that point of view. Still, best to avoid those sorts of snafu in the first place;)

Permalink to Comment

28. JPZaragoza on May 29, 2012 11:13 AM writes...

Take a look at the company's creepy website. Go to stock info ( see that they contend the fair market value of the company is $2.5 billion. What do these guys smoke? Being involved with this company erases your credibility.

Permalink to Comment

29. Vader on May 29, 2012 11:26 AM writes...


This ain't a divorce. It's your blind date who you dropped off at her door after a thoroughly miserable dinner and movie suing you for palimony.

Permalink to Comment

30. Anonymous on May 29, 2012 12:04 PM writes...

"GSK is a loser in the MS market and will continue to be a loser"

Exactly 5 years ago, GSK set up a research center in China to work on MS, Parkinson's and Alzheimers. According to the GSK product pipeline on their website, they do not have anything in development for those three diseases that was developed internally. And now we know that they were in conversations with this guy at IRBP who has a degree from Jerry Falwell's Liberty University. Oh, and they're (still!) developing an in-licensed small molecule integrin (VLA4) antagonist for MS. Really? Seriously?

So, can anyone refute his statement? They wouldn't be on the top of my list if I wanted to partner a MS drug.......and neither would IRBP. The fact that these two companies were in negotiations speaks volumes about both their management teams.

Permalink to Comment

31. Nick K on May 29, 2012 1:18 PM writes...

@ToughChoices: Touch a nerve, did I? You're remarkably thin-skinned for a PR shill....

Permalink to Comment

32. weird guy on May 29, 2012 1:44 PM writes...

Thumbs up for the language that Mr. Buswell used. I wish in academia people were more like that, just get up after a talk and say "your research is BS"

Permalink to Comment

33. My 0.02 on May 29, 2012 2:58 PM writes...

@26 and 30,

Are we sure that Mr. Buswell is not related to the people who started Nativis pharma?

Permalink to Comment

34. OrphanReceptor on May 29, 2012 3:42 PM writes...

Thanks for that, it really made me laugh. Losing one's cool in public like this is of course a definite no-no but I can well imagine that dealing with GSK MBA types is enough to stretch anyone's sanity to breaking point. Someone mentioned earlier about the use of first names for senior managers @GSK. That was certainly the case when I was there when everyone talked about "JP" and "Tachi" as though they were our best buddies! "JP" even gave us an extra holiday called a "JP day" almost every year for our "great work". Alas, many of us got the sack while enjoying our JP day, JP certainly had a sense of humour.

Permalink to Comment

35. partial agonist on May 29, 2012 4:51 PM writes...

"...Master’s degree MA in Management & Leadership from Liberty University"

If you haven't seen it yet,
google Bill Maher Liberty University

Maher noted that Liberty teaches "creation science," and the idea that earth was created 5,000 years ago. "This is a school you flunk out of when you get the answers right," he joked.

Much as conservatives believe gay marriage cheapens their own vows, he said "I think a diploma from Liberty cheapens my diploma from a real school".

Permalink to Comment

36. Anonymous on May 29, 2012 6:14 PM writes...

It looks like immune response biopharma is a rehashing of an older pump-and-dump stock scheme, originally collaborating with Pfizer. The company filed for bankruptcy, and then miraculously, a company with almost the exact same name and many of the same board members reformed, touting the same research interests and claiming to be completely independent. One former investor has chronicled the series of events here That blog has even attracted the same type of breathless threats of legal action that we have come to know and love from the Burzynski clinic. Can we say scam artists hard at work?

Permalink to Comment

37. Anonymous on May 29, 2012 9:51 PM writes...

Reverbative? Objurgatory? The only people I know who use words like that are pompous jackasses who think vocabulary is an acceptable substitute for scientific knowledge. GSK non-hierarchical? I'll be looking for Patrick, Moncef, and Andrew's names when the next round of layoffs sweep through then.

Permalink to Comment

38. David Buswell on May 30, 2012 1:05 AM writes...

Hello Derek,

I found your article about our ending of the partnership with GSK, let me clarify the situation, you made some incorrect assumptions.

The first point you do have correct about the frustration on both sides that a deal did not get done which is most unfortunate for MS patients who will have to wait to get NeruoVax.

GSK is a very big organization and the central nervous system neurology unit of GSK is led in Belgium and Canada, we had a very good working relationship with them for over 6 months. Both sides worked very hard to get a fair deal for all parties. GSK's CNS GSKBIO Division wanted the drug very badly and needed the drug to fill a hole in their pipeline.

What it comes down to in a bureaucracy like GSK with multiple committees and executive committees to endorse these deals takes a very long time, and senior management has the final say. The director of operations wanted this drug for his team very much and so did the Canadian CNS operations head both wanted NeuroVax and put forth a strong clinical and scientific package to their senior management which is where things got bizarre for all parties.

What it boils down to probably earnings and holding back on projects as they don't know what their earnings are going to look like with the HGSI deal their senior management is focused upon. GSK called it a blow for both companies and its unfortuate that the senior management did not go with the recommendation of their directors and licensing managers who run the GSKBIO division.

GSK still wanted to do a collaboration with us but we felt it was best to terminate the relationship. I talked to both GSKBIO operations heads and both wanted to pursue a collaboration internally at GSK even after their senior management failed to endorse the deal. It leaves them without a drug and us without a partner in the short term.

They were the right and wrong partner, right in they had no MS drug and wrong that they don't have a lot of experience and they are a very bureaucratic organization. We as a small company can do things they can't but we are in talks with other partners.

But getting back to your article it is incorrect and misrepresents the situation which i hope i have clarified, and i hope that you will update your article. I am frustrated at the senior management of GSK and the comments were directed to them they are bean counters and have a lot of money and power. Perhaps my comments were heated and i felt GSK senior management needed a reality check and i blasted them in hindsight maybe it was not the best thing to do. But we terminated the relationship, in fact the GSK BIO heads were reluctant to tell us that they did not get the funding ok from senior management. Like i said they said its a blow for both sides.

But they science for NeuroVax is solid, and Dr. Bourdette the lead clinician at OHSU says of all the drugs he has used the NeuroVax works the best even better than Avonex. We ended the relationship not GSK so i would correct and revise your article with the real facts not speculation which you alluded to. Look its bad for both companies but the sun will shine....

Best Regards, David

Mr. David Buswell CEO IRBP

Permalink to Comment

39. CR on May 30, 2012 12:05 PM writes...

Nothing like a one-sided story, thanks Mr. Buswell. So, let us get this straight - YOU terminated the project, but still want to blast GSK? As many people have stated on this board, good luck trying to get another deal. Sounds a lot like the conversation I have with my elementary school daughter.

Permalink to Comment

40. Anonymous on May 30, 2012 12:48 PM writes...

No matter which side of this controversy you come down on, all can agree: the CEO of Immune Response Biopharma is a HORRIBLE writer. The press release, the comment above and their website display the writing skills of a third grader.

Permalink to Comment

41. Anonymous on May 30, 2012 12:48 PM writes...

No matter which side of this controversy you come down on, all can agree: the CEO of Immune Response Biopharma is a HORRIBLE writer. The press release, the comment above and their website display the writing skills of a third grader.

Permalink to Comment

42. molecular architect on May 30, 2012 1:04 PM writes...

Wow, a CEO that needs a course in remedial grammar.

Mr. Buswell, please get reacquainted with the concept and use of the "comma" (,) to separate dependent clauses. Your writing skills are truly atrocious for someone with a Masters Degree, even one from such a prestigious university as Liberty.

Permalink to Comment

43. David Formerly Known as a Chemist on May 30, 2012 1:25 PM writes...

Mr. Buswell, the deal didn't get done. Move on and find another partner or financing route. Unfortunately, your public rant just made both those opportunities several orders of magnitude more difficult. Would you go back and hire a job applicant you initially rejected, who then went and publicly wrote such a diatribe against you or your company? Didn't think so.

Your press release was certainly amusing, but in a pitiful way. Always maintain professionalism. Your clarification on Derek's blog did nothing to fix the damage you created. Big pharma is difficult to work with, everyone knows that.

Permalink to Comment

44. CR on May 30, 2012 2:35 PM writes...

One more question for Mr. Buswell:

You state, "GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money."

Can you please remind the audience how many approved MS drugs you have? What is that? Zero? Pot (GSK) this is kettle (Mr. Buswell) calling...

Permalink to Comment

45. My 0.02 on May 30, 2012 11:31 PM writes...

The professionalism Mr Buswell displayed reminds me salesman in the electronics stores on the 5th avenue in New York City back in the 80's. Anyone who ventured into one of these stores and came out empty-handed would know exactly what I mean.

Permalink to Comment

46. Anonymous on June 1, 2012 7:29 PM writes...

All your comments obsessing about grammar are amusing. You’re very righteous about it.
If you don't eat your meat, you can't have any pudding!

Permalink to Comment

47. David Buswell on June 21, 2014 3:08 AM writes...

How are all of the little people the Internet haters & trolls who are personally envious & jealous of me doing not good from the looks of the hate. Derek too tried to embarrass me and refused to retract his incorrect statements.

Immune Response BioPharma under my leadership & watch now positioned for success & partnering since this blog was posted now NeuroVax has the FDA endorsements Orphan Pediatric & SPMS Fast Track Designations. I didn't make any mistakes big pharma miscalculated so did you trolls they will just have to pony up more $$$ sooner or later, we are blooming without them.

I've been busy let me give you the 411 on NeuroVax milestones now has FDA Pediatric Orphan Designation & FDA Fast Track Designation for SPMS, and our new study Phase IIb to begin in mid 2015.

IRBP milestones REMUNE HIV/AIDS Vaccine FDA Pediatric Orphan Designation & now ready for BLA filing first HIV/AIDS Vaccine to market. Remune is the only viable vaccine most tested & advanced HIV/AIDS vaccine in history still better then anything to come along in 30 years.

Now IRC pipeline one of the original biotechs now under IRBP umbrella becomes the next great biotech, demonstrating why i am the best there is, was or ever will be. Don't hate the player hate that someone works harder then you, you trolls can KMA.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry